Show simple item record

dc.contributor.authorBoussios, Stergios
dc.contributor.authorMikropoulos, Christos
dc.contributor.authorSamartzis, Eleftherios
dc.contributor.authorKarihtala, Peeter
dc.contributor.authorMoschetta, Michele
dc.contributor.authorSheriff, Matin
dc.contributor.authorKarathanasi, Afroditi
dc.contributor.authorSadauskaite, Agne
dc.contributor.authorRassy, Elie
dc.contributor.authorPavlidis, Nicholas
dc.date.accessioned2020-05-23T01:12:44Z
dc.date.available2020-05-23T01:12:44Z
dc.date.issued2020-05-21
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/305714
dc.description.abstractEpithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women. Two-thirds of patients present at advanced stage at diagnosis, and the estimated 5 year survival rate is 20−40%. This heterogeneous group of malignancies has distinguishable etiology and molecular biology. Initially, single-gene sequencing was performed to identify germline DNA variations associated with EOC. However, hereditary EOC syndrome can be explained by germline pathogenic variants (gPVs) in several genes. In this regard, next-generation sequencing (NGS) changed clinical diagnostic testing, allowing assessment of multiple genes simultaneously in a faster and cheaper manner than sequential single gene analysis. As we move into the era of personalized medicine, there is evidence that poly (ADP-ribose) polymerase (PARP) inhibitors exploit homologous recombination (HR) deficiency, especially in breast cancer gene 1 and 2 (BRCA1/2) mutation carriers. Furthermore, extensive preclinical data supported the development of aurora kinase (AURK) inhibitors in specific tumor types, including EOC. Their efficacy may be optimized in combination with chemotherapeutic or other molecular agents. The efficacy of metformin in ovarian cancer prevention is under investigation. Certain mutations, such as ARID1A mutations, and alterations in the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway, which are specific in ovarian clear cell carcinoma (OCCC) and endometrioid ovarian carcinoma (EnOC), may offer additional therapeutic targets in these clinical entities. Malignant ovarian germ cell tumors (MOGCTs) are rare and randomized trials are extremely challenging for the improvement of the existing management and development of novel strategies. This review attempts to offer an overview of the main aspects of ovarian cancer, catapulted from the molecular mechanisms to therapeutic considerations.
dc.languageen
dc.publisherMDPI
dc.subjectovarian cancer
dc.subjectnext-generation sequencing
dc.subjecthomologous recombination repair
dc.subjectPARP inhibitors
dc.subjectAURK inhibitors
dc.subjectmetformin
dc.subjectpersonalized treatment
dc.titleWise Management of Ovarian Cancer: On the Cutting Edge
dc.typeArticle
dc.date.updated2020-05-23T01:12:43Z
prism.issueIdentifier2
prism.publicationNameJournal of Personalized Medicine
prism.volume10
dc.identifier.doi10.17863/CAM.52792
dcterms.dateAccepted2020-05-19
rioxxterms.versionofrecord10.3390/jpm10020041
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidBoussios, Stergios [0000-0002-2512-6131]
dc.identifier.eissn2075-4426


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record